Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

Effects of immunomodulators on acute Trypanosoma Cruzi infection in mice.

Walter T Hughes, Helieh S Oz, Elaine K Thomas, Craig J McClain

Med Sci Monit 2002; 8(6): BR208-211

ID: 420822

BACKGROUND: Patients who recover from acute trypanosomiasis may succumbto chronic Chagas' disease later in life due to age related immunosuppression, immune system disorderssuch as AIDS, or during periods of immunosuppressive therapy for organ transplantation. In this study,effects of immunomodulators with diverse properties were examined on the course of an acute and lethalTrypanosoma cruzi infection.MATERIAL/METHODS: ICR (Swiss) mice inoculated with Tulahuen (lethal) strainof T. cruzi were treated with 6 different immunomodulators and the course of infection was studied.RESULTS:Tacrolimus (FK-506) and dexamethasone increased parasitemia in mice when compared to infected untreatedanimals. Mycophenolate mofetil (RS-61443) and recombinant interleukin-15 (IL-15) treatment decreasedthe number of parasites but had no effect on animal survival. In contrast, compound L-685-818 (tacrolimusanalog) and CD40 ligand (CD40L), provided protection against lethal infection. Mice that survived initialinfection were all protected against reinfection.CONCLUSIONS: This study demonstrates the dangers ofimmunosuppression with tacrolimus and dexamethasone in T. cruzi infected subjects. While mycophenolatedid not exacerbate the infection, our data suggest potential therapeutic applications for L-685-818 andCD40 ligand in trypanosomiasis.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree